Avience Biomedicals Limited IPO Details
Factual IPO information from public filings. Not investment advice.
Issue Details
- Price Band
- ₹196 – ₹208
- Lot Size
- 600 shares
- Min. Investment
- ₹1,24,800
- Total Issue Size
- ₹30.24 Cr
- 14,53,800 shares
- Fresh Issue
- ₹30.24 Cr
- 14,53,800 shares
- Offer for Sale
- ₹0 Cr
- Face Value
- ₹10 per share
- Issue Type
- Book-built IPO
- Listing At
- NSE SME
- Shares Pre-Issue
- 40,31,256
- Shares Post-Issue
- 54,85,056
Lot Size & Investment
1 lot = 600 shares
Retail (min)
2 lots · 1,200 shares
Retail (max)
2 lots · 1,200 shares
S-HNI (min)
3 lots · 1,800 shares
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 2 | 1,200 | ₹2,49,600 |
| Small HNI (S-HNI) | 3 | 1,800 | ₹3,74,400 |
| Big HNI (B-HNI) | 9 | 5,400 | ₹11,23,200 |
Financial Performance
Restated figures in ₹ crore, unless stated otherwise
| Period | Jan-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 24.37 |
| Profit After Tax | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| Net Worth | 28.52 | 22.78 | 6.21 |
| Reserves & Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowing | 26.73 | 22.16 | 15.13 |
Key Performance Indicators
| Period | Jan-06 | Mar-25 |
|---|---|---|
| ROE (%) | 22.38 | 50.14 |
| ROCE (%) | 16.99 | 24.84 |
| EPS (₹) | — | 17.94 |
| P/E (pre-issue) | — | 11.59 |
| P/E (post-issue) | — | 16.56 |
About Avience Biomedicals Limited
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets. The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the Company also act as distributors and traders of medical equipment. The company's manufacturing unit is situated in Noida, Uttar Pradesh. The company offers a comprehensive range of diagnostic solutions, including: Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test. Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit. Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY. Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer. Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM). As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees Competitive Strength Strong Industry Experience and Expertise. Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits. Strong distribution network across India and is growing its international footprint. Cost-Effective and Affordable Solutions. Stringent quality control processes and complies with ISO standards and regulatory approvals.
Company Information
- Book running lead managers
- Fintellectual Corporate Advisors Pvt.Ltd.
- Registered office
- C-11, Block-C, Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
- Market maker
- Asnani Stock Broker Pvt.Ltd.